Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies.
The company developed a proprietary anti-PD-1 antibody, called ANB011, with key differentiating advantages over competitors using its SHM-XEL platform.
In addition, it is also developing novel antibodies against other immune checkpoint receptors, including TIM-3 and LAG-3.
By blocking the interaction of PD-1, TIM-3 and LAG-3 with their respective ligands, the company's immunotherapy portfolio aims to restore immune function in cancer patients across a variety of tumor types.
Apart from immunotherapy portfolio, the company has used its SHM-XEL platform to develop programs for pustular psoriasis, atopic dermatitis, muscle wasting disorders, fibrosis and antibody drug conjugate applications.
AnaptysBio president and CEO Hamza Suria said the company's SHM-XEL platform has permitted to generate high potency antibodies against multiple immune checkpoint receptors.
"We believe combination immunotherapy is an exciting paradigm in oncology and has the potential to provide durable anti-tumor effects for a broad range of patients," Suria added.